Zobrazeno 1 - 10
of 37
pro vyhledávání: '"D. Marsman"'
Autor:
Nathan den Broeder, Alfons A den Broeder, Aatke van der Maas, Frank H. J. van den Hoogen, D. Marsman
Publikováno v:
The Lancet. Rheumatology, 3, e758-e766
The Lancet. Rheumatology, 3, 11, pp. e758-e766
The Lancet. Rheumatology, 3, 11, pp. e758-e766
Summary Background Glucocorticoids remain the cornerstone of polymyalgia rheumatica treatment, but their use has several drawbacks, such as long treatment duration and glucocorticoid-related adverse events. Effective glucocorticoid-sparing agents wit
Publikováno v:
Annals of the Rheumatic Diseases. 81:377-378
BackgroundGlucocorticoids (GC) are the cornerstone of treatment in Polymyalgia rheumatica (PMR) [1]. However, they are associated with considerable toxicity and inefficacy in part of the patients. Rituximab (RTX) was effective for PMR in a 21-week ra
Autor:
Calin D. Popa, Dirkjan van Schaardenburg, Ed N. Griep, Mirian Starmans-Kool, D. Marsman, Laurette van Boheemen, Michael T. Nurmohamed, Wouter H Bos, Alper M. van Sijl, Marian H. van Beers-Tas, Samina A. Turk, Maarten Boers
Publikováno v:
RMD Open, 7(1):e001591. BMJ Publishing Group
RMD open, 7(1):e001591. BMJ Publishing Group
RMD Open, Vol 7, Iss 1 (2021)
RMD Open
van Boheemen, L, Turk, S, Beers-Tas, M V, Bos, W, Marsman, D, Griep, E N, Starmans-Kool, M, Popa, C D, van Sijl, A, Boers, M, Nurmohamed, M T & van Schaardenburg, D 2021, ' Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: Results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial ', RMD Open, vol. 7, no. 1, e001591 . https://doi.org/10.1136/rmdopen-2021-001591
RMD open, 7(1):e001591. BMJ Publishing Group
RMD Open, Vol 7, Iss 1 (2021)
RMD Open
van Boheemen, L, Turk, S, Beers-Tas, M V, Bos, W, Marsman, D, Griep, E N, Starmans-Kool, M, Popa, C D, van Sijl, A, Boers, M, Nurmohamed, M T & van Schaardenburg, D 2021, ' Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: Results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial ', RMD Open, vol. 7, no. 1, e001591 . https://doi.org/10.1136/rmdopen-2021-001591
ObjectivesPersons at high risk of rheumatoid arthritis (RA) might benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying effects of statins in patients with RA as well as an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a52ebb5bb7e0e3ad5eef3550b93c042
https://research.vumc.nl/en/publications/216fdbf1-4b47-49aa-9b2f-da296778c04b
https://research.vumc.nl/en/publications/216fdbf1-4b47-49aa-9b2f-da296778c04b
Autor:
Nathan den Broeder, Thomas Bolhuis, Aatke van der Maas, D. Marsman, Alfons A den Broeder, Frank J. A. van den Hoogen
Publikováno v:
Rheumatology International, 41, 3, pp. 611-616
Rheumatology International, 41, 611-616
Rheumatology International, 41, 611-616
Item does not contain fulltext Guidelines on management of polymyalgia rheumatica (PMR) recommend early introduction of methotrexate (MTX), especially in patients with worse prognosis, although evidence on clinical efficacy of MTX in PMR is limited.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49021e5ca51c022f49800a5363c621c1
https://repository.ubn.ru.nl/handle/2066/232580
https://repository.ubn.ru.nl/handle/2066/232580
Publikováno v:
Annals of the Rheumatic Diseases. 80:399.2-400
Background:Corticosteroids remain the cornerstone of polymyalgia rheumatica treatment, but their use has several disadvantages such as long treatment duration and glucocorticoid-related adverse events.1,2 Data on evidence based effective glucocortico
Autor:
Samina A. Turk, D. Marsman, Maarten Boers, E. N. Griep, Calin D. Popa, L. Van Boheemen, Wouter H Bos, M. Starmans, M. H. Van Beers Tas, Michael T. Nurmohamed, A.M. van Sijl, D. van Schaardenburg
Publikováno v:
Annals of the Rheumatic Diseases. 79:1415.2-1416
Background:Persons at high risk for developing rheumatoid arthritis (RA) may benefit from a low-risk pharmacological intervention aimed at primary prevention. Statins are safe and widely-used drugs; previous studies demonstrated disease-modifying eff
Autor:
N. Den Broeder, T. Bolhuis, A. van der Maas, A.A. den Broeder, F.H.J. van den Hoogen, D. Marsman
Publikováno v:
Annals of the Rheumatic Diseases. 79:688.2-688
Background:Guidelines on polymyalgia rheumatica (PMR) recommend early introduction of methotrexate (MTX), especially in patients with worse prognosis such as flare or glucocorticoid (GC)-related adverse events (AE).1GC-AE are reported in up to 65% of
Publikováno v:
Annals of the Rheumatic Diseases. 79:1550.1-1551
Background:The cause for polymyalgia rheumatica (PMR) is currently unknown. Disease onset may be triggered by a combination of genetic predisposition and environmental factors such as infection.1In different regions of Denmark a simultaneous peak inc
Autor:
Scott Michael Pernia, Justin O'Day, J. Kuhn, Gordon Carichner, Richard B. Brown, Sundus Kubba, Eric D. Marsman, Michael Shannon McCorquodale
Publikováno v:
IEEE Transactions on Circuits and Systems I: Regular Papers. 56:943-956
Recent trends in the development of integrated silicon frequency sources are discussed. Within that context, a 25-MHz self-referenced solid-state frequency source is presented and demonstrated where measured performance makes it suitable for replacem
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.